Biogen Inc. BIIB
Healthcare · Drug Manufacturers - General · United States · S&P 500
Based on the available data, Biogen Inc. gets an algorithmic score of 62/100. It trades at 227.07 $, with a bullish technical trend (RSI 61.0) and 35.0% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low-debt balance sheet.
- Attractive free-cash-flow yield (5.9%).
- Low beta (0.57): defensive profile.
Weaknesses
- Low ROE (4.6%).
- Shrinking revenue (-0.9% per year).
Fundamentals
| P/E | 40.40 |
| Forward P/E | 13.73 |
| PEG | 2.35 |
| P/B | 1.78 |
| EV/EBITDA | 12.09 |
| P/S | 3.35 |
| ROE % | 4.58 |
| ROA % | 5.21 |
| Gross margin % | 78.32 |
| Operating margin % | 25.06 |
| Net margin % | 8.32 |
| Revenue growth % (y/y) | 3.40 |
| Earnings growth % (y/y) | -84.80 |
| Revenue CAGR % | -0.94 |
| Earnings CAGR % | -24.85 |
| Debt/Equity % | 44.33 |
| Current ratio | 1.86 |
| FCF yield % | 5.87 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | +3.9 % |
| 3 months | +5.1 % |
| 6 months | +21.1 % |
| YTD | +27.7 % |
| 1 year | +65.3 % |
| 3 years | -11.9 % |
| 5 years | -23.2 % |
Risk
| 1-year volatility | 35.0 % |
| Beta | 0.57 |
| 5-year max drawdown | -64.3 % |
| Sharpe 1A | 1.50 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.